MedPath

DE-117 Spectrum 5 Study

Phase 3
Completed
Conditions
Primary Open-angle Glaucoma and Ocular Hypertension
Interventions
Drug: DE-117 Ophthalmic Solution
Registration Number
NCT03697811
Lead Sponsor
Santen Inc.
Brief Summary

Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
107
Inclusion Criteria
  • Patients with Primary Open-Angle Glaucoma or Ocular Hypertension in one or both eyes.
  • Provide signed written informed consent.
  • Diagnosis of POAG or OHT in both eyes.
  • Qualifying corrected visual acuity in each eye.
  • Qualifying central corneal thickness in each eye.
  • Qualifying Day 1 IOP measurement at 3 time-points in both eyes after latanoprost Run-in Period.
  • Qualifying Anterior chamber angle.
  • Qualifying IOP measurement at 3 time-points during latanoprost Run-in Period.
Exclusion Criteria
  • Patients who cannot safely discontinue use of Ocular Hypotensive Medications during Washout.
  • Patients with prior exposure to DE-117.
  • History of ocular surgery specifically intended to lower IOP
  • Advanced glaucoma in either eye.
  • Any corneal abnormality or other condition interfering with or preventing reliable Goldmann applanation tonometry.
  • Any ocular surgery or ocular laser treatment within 180 days prior to Visit 1 (Screening) and throughout the study in either eye.
  • Females who are pregnant, nursing, or planning a pregnancy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
DE-117 Ophthalmic Solution 0.002%DE-117 Ophthalmic SolutionInterventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
Primary Outcome Measures
NameTimeMethod
Change From Baseline in Mean Diurnal Intraocular Pressure (IOP) at Month 3.Month 3

IOP lowering effect of DE-117 ophthalmic solution 0.002% in Latanoprost low/non-responder subjects. Mean Diurnal Intraocular Pressure: Analysis of Change from Baseline in IOP score at Month 3 using Paired T-test on Observed Case. Mean Diurnal IOP is defined as the average IOP of all three timepoints (8:00,12:00, 16:00) at Month 3.

Secondary Outcome Measures
NameTimeMethod
Change From Baseline in IOP at Timepoints at Week 208:00, 12:00 and 16:00 at Week 2

Change in mean IOP were evaluated at each time point at all post-baseline visits. (Change from baseline measurement at each timepoint was calculated by deducting the baseline value at corresponding timepoint from the IOP measurement).

Change From Baseline in Mean Diurnal IOP at Week 2 and Week 6week 2 and 6

Change from baseline (Visit 4) in mean diurnal IOP at Week 2 (Visit 5) and Week 6 (Visit 6).

Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Month 308:00, 12:00 and 16:00 at month 3.

Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.

Change From Baseline in IOP at Timepoints at Week 608:00, 12:00 and 16:00 at Week 6

Change in mean IOP were evaluated at each time point at all post-baseline visits.

Percent Change From Baseline in Mean Diurnal IOP at Week 2, Week 6 and Month 3week 2, 6 and month 3

The secondary efficacy endpoint evaluated percent change from baseline in mean DIOP at week 2, 6 and month 3.

Change From Baseline in IOP at Timepoints at Month 308:00, 12:00 and 16:00 at month 3

Change in mean IOP were evaluated at each time point at all post-baseline visits.

Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Week 208:00, 12:00 and 16:00 at week 2

Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.

Intraocular Pressure: Percent Change From Baseline by Analysis Visit and Timepoint at Week 608:00, 12:00 and 16:00 at week 6

Intraocular Pressure: Percent Change from Baseline by Analysis Visit and Timepoint.

Trial Locations

Locations (32)

Asheville Eye Associates, PLLC

🇺🇸

Asheville, North Carolina, United States

Shettle Eye Research, Inc.

🇺🇸

Largo, Florida, United States

Glaucoma Consultants and Center for Eye Research, PA

🇺🇸

Mount Pleasant, South Carolina, United States

Total Eye Care PA

🇺🇸

Memphis, Tennessee, United States

Apex Eye Clinical Research, LLC

🇺🇸

Cincinnati, Ohio, United States

Dixon Eye Care

🇺🇸

Albany, Georgia, United States

Heart of America Eye Care, P.A.

🇺🇸

Shawnee Mission, Kansas, United States

Eye Research Foundation

🇺🇸

Newport Beach, California, United States

North Bay Eye Associates

🇺🇸

Petaluma, California, United States

VRF Eye Specialty Group

🇺🇸

Memphis, Tennessee, United States

Arizona Eye Center

🇺🇸

Chandler, Arizona, United States

Global Research Management

🇺🇸

Glendale, California, United States

North Valley Eye Medical Group

🇺🇸

Mission Hills, California, United States

Martel Eye Medical Group

🇺🇸

Rancho Cordova, California, United States

Danbury Eye Physicians & Surgeons

🇺🇸

Danbury, Connecticut, United States

International Eye Associates, PA

🇺🇸

Ormond Beach, Florida, United States

Coastal Research Associates, LEC

🇺🇸

Roswell, Georgia, United States

Comprehensive Eye Care Ltd

🇺🇸

Washington, Missouri, United States

NYU Langone Health Department of Ophthalmology

🇺🇸

New York, New York, United States

Rochester Ophthalmological Group, PC

🇺🇸

Rochester, New York, United States

Clayton Eye Clinical Research, LLC

🇺🇸

Morrow, Georgia, United States

Tekwani Vision Center

🇺🇸

Saint Louis, Missouri, United States

South Shore Eye Center

🇺🇸

Wantagh, New York, United States

Mundorf Eye Center

🇺🇸

Charlotte, North Carolina, United States

Cornerstone Health Care

🇺🇸

High Point, North Carolina, United States

Abrams Eye Center

🇺🇸

Cleveland, Ohio, United States

Scott & Christie and Associates PC

🇺🇸

Cranberry Township, Pennsylvania, United States

The Eye Institute

🇺🇸

Tulsa, Oklahoma, United States

Texas Eye, PA

🇺🇸

Austin, Texas, United States

Eye Clinic of Texas

🇺🇸

League City, Texas, United States

Nashville Vision Associates

🇺🇸

Nashville, Tennessee, United States

Medical Center Ophthalmology Associates

🇺🇸

San Antonio, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath